Faculty Opinions recommendation of Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug.

2017 ◽  
Author(s):  
Paul Drawz
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Aminopeptidase A ◽  
Aminopeptidase A Inhibitor ◽  
Dose Escalating

Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug

2013 ◽  
Vol 53 (4) ◽  
pp. 385-395 ◽  
Author(s):  
Fabrice Balavoine ◽  
Michel Azizi ◽  
Damien Bergerot ◽  
Nadia De Mota ◽  
Rémi Patouret ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Aminopeptidase A ◽  
Aminopeptidase A Inhibitor ◽  
Dose Escalating

NXY-059 Does Not Affect Bleeding Time in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Phase I Study

2007 ◽  
Vol 47 (2) ◽  
pp. 264-272 ◽  
Author(s):  
Dag Nilsson ◽  
Johan Wemer ◽  
Yi-Fang Cheng ◽  
Ingalill Reinholdsson ◽  
Gunnar Englund ◽  
...  
Keyword(s):  
Phase I ◽  
Healthy Volunteers ◽  
Phase I Study ◽  
Bleeding Time ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Crossover Phase

Sa1767 - Eb8018, a Novel Fimh Blocker is well Tolerated in a Randomized, Double-Blind, Placebo -Controlled Phase I Study in Healthy Volunteers

2018 ◽  
Vol 154 (6) ◽  
pp. S-387
Author(s):  
Jaikrishna Patel ◽  
Jean-Michel Paillarse ◽  
Patricia Françon ◽  
Arnaud Laveissière ◽  
Christophe Bonny ◽  
...  
Keyword(s):  
Phase I ◽  
Healthy Volunteers ◽  
Phase I Study ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document